SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials is a research paper published in Pharmaceutical Statistics (2022). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CA264257
National Institutes of Health
Grant: R21
National Institutes of Health
Grant: CA082709
National Institutes of Health
Grant: P30
NCI NIH HHS
Grant: P30 CA082709
NCI NIH HHS
Grant: R21 CA264257
National Science Foundation
Grant: 2047631
CAREER: Mining biological functions from single cell multi-omics data
National Institutes of Health
Grant: 1R21CA264257-01
Curve-free phase I/II clinical trial designs for molecularly targeted agents and immunotherapy
National Institutes of Health
Grant: 3P30CA082709-16S3
Indiana University Melvin and Bren Simon Cancer Center Support Grant
Louisiana Board of Regents
National Science Foundation of Sri Lanka
Indiana University
FWCI
1.10
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals